Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
IgAN: full-pipeline trial registry
4 of 4 indexed IgAN trials are currently recruiting.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 4 currently recruiting · #4,115 of 28,707 conditions by registered trial count
IgAN: 4 US clinical trials tracked, 4 recruiting.
IgAN is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Alexion Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition igan
OPEN 4 | RECR 100% | LATE 2 | EARLY 2 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
IgAN lists 4 open slots (100% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for IgAN on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
IgAN is recruiting above its size-band peers.
4 of 4 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Alexion Pharmaceuticals
NCT06291376
Atacicept in Multiple Glomerular Diseases
Vera Therapeutics
NCT06983028
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
ADARx Pharmaceuticals
NCT06989359
Study of Ravulizumab in Pediatric Participants With Primary IgAN
Alexion Pharmaceuticals
NCT07024563
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on IgAN records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on IgAN trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this IgAN page
4 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 IgAN trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Alexion Pharmaceuticals sponsors the most IgAN trials on record, review their full trial history before evaluating a specific study. See Alexion Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This IgAN condition card totals 4 registered trials; most-linked intervention Ravulizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.